MedTrace Logo

R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

NCT05777369 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-03-21

No results posted yet for this study

Summary

To evaluate the efficacy and safety of R-CMOP regimen based on mitoxantrone hydrochloride liposome injection in the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL) based on cardiac function screening

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

DRUG

Rituximab

375 mg/m2, d0

DRUG

Mitoxantrone hydrochloride liposome

18 mg/m2, d1

DRUG

Cyclophosphamide

750 mg/m2, d1

DRUG

Vincristine/Vindesine

Vincristine: 1.4 mg/m2, d1(The maximum dose was 2 mg) Vindesine: 3 mg/m2, d1

DRUG

Prednisone

60 mg/m2, d1\~d5

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Wei Xu, PhD& MD · The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2023-08-31
Completion
2024-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05777369 on ClinicalTrials.gov